REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients

In February 09-10 2023 the REVERT partners met in Cartagena and Murcia to
discuss about the activities carried out since the beginning of the project, led by San
Raffaele Research Center of Rome.
The two-day meeting was organised by the Spanish partners of the project: Servicio
Murciano del Salud, Instituto Murciano de Investigación Biosanitaria (IMIB), Fundación
para la Formación e Investigación Sanitarias de la Región de Murcia and UCAM
Universidad Católica San Antonio de Murcia.
The focus of the consortium meeting was to share the different research institutes,
clinical centers and biobanks perspectives and identify the next steps of the
REVERT clinical study, which aims to develop an innovative combinatorial therapy
model capable of identifying more efficient and cost-effective therapeutic intervention
for patients with unresectable metastatic colorectal cancer (mCRC), with the support
of predictive medicine and artificial intelligence (AI).
ProMIS, the partner in charge of the communication and dissemination activities, will
support in the following months all the partners in the engagement of local, national
and international stakeholders for promoting the study and its results.